Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir + Daclatasvir in HCV Genotype 1b
NCT02268864Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2015
- Primary completion
- Jan 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of simeprevir in chronic hepatitis C (CHC), sponsored by Janssen Pharmaceutical. Started Jan 2015; status: completed.
02
Drugs
simeprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT02268864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268864.